article thumbnail

STAT+: AI drug firm Recursion moves from survival to industry domination

STAT

. The company — or, at least, what existed at its founding in 2013 — hoped to pull data from images of healthy and diseased cells, and use that data to identify drugs gathering dust on pharmaceutical company shelves that could be repurposed as rare disease treatments. 

article thumbnail

STAT+: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA

STAT

BOSTON — FDA Commissioner Robert Califf said on Monday that it “bothers” him that Novo Nordisk, which makes an obesity medication, funded the development of obesity coursework for medical schools.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novartis offers $17.7m support in the fight for health equity

Outsourcing Pharma

The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.

article thumbnail

TPD Assay Development & Screening Summit

pharmaphorum

Expert speaking companies include Plexium , Stanford University Medical School, Seed Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson, Kymera Therapeutics, Foghorn Therapeutics & many more. View the full event guide here.

article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

She has worked with regulatory agencies and pharmaceutical companies for over 10 years. She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. Before that she has been an independent scientific advisor. About the author.

article thumbnail

AI-Enabled Persona and Next Best Actions: Speculative Use Case

PharmaState Academy

In a highly competitive and constantly evolving industry, pharmaceutical companies must be able to identify and understand the needs and preferences of their target audiences and develop tailored marketing campaigns to effectively reach them. You went to medical school with them,” – and then invite them to the webinar.

article thumbnail

To increase clinical trial diversity, build trust in communities and use tech wisely

pharmaphorum

Buchanan’s group is working with Historically Black Colleges and Universities that have medical schools to encourage that participation. Pros and cons of decentralised trials for marginalised communities. Additionally, though, having researchers of colour leading the studies will go a long way.